186 related articles for article (PubMed ID: 16514302)
1. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS
AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302
[TBL] [Abstract][Full Text] [Related]
2. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
Loutfy MR; Harris M; Raboud JM; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley SL; Montaner JS
HIV Med; 2007 Oct; 8(7):427-32. PubMed ID: 17760734
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
True AL; Chiu YY; Demasi RA; Stout R; Patel I
Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
[TBL] [Abstract][Full Text] [Related]
4. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
Gottlieb M; Thommes JA;
Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056
[TBL] [Abstract][Full Text] [Related]
5. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
Lalezari JP; Saag M; Walworth C; Larson P
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):805-13. PubMed ID: 18507525
[TBL] [Abstract][Full Text] [Related]
6. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A
Antivir Ther; 2008; 13(3):449-53. PubMed ID: 18572758
[TBL] [Abstract][Full Text] [Related]
7. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
[TBL] [Abstract][Full Text] [Related]
8. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL
Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257
[TBL] [Abstract][Full Text] [Related]
9. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
10. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
[TBL] [Abstract][Full Text] [Related]
11. Enfuvirtide and cutaneous injection-site reactions.
Mirza RA; Turiansky GW
J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
[TBL] [Abstract][Full Text] [Related]
12. Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study.
Shalit P; True A; Thommes JA;
HIV Clin Trials; 2007; 8(1):24-35. PubMed ID: 17434846
[TBL] [Abstract][Full Text] [Related]
13. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
Rice C; Wilantewicz H
AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
[TBL] [Abstract][Full Text] [Related]
15. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.
Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A
New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088
[TBL] [Abstract][Full Text] [Related]
16. Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
Glutzer E
AIDS Read; 2003 Mar; 13(3 Suppl):S14-6. PubMed ID: 12765161
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.
Zhang X; Nieforth K; Lang JM; Rouzier-Panis R; Reynes J; Dorr A; Kolis S; Stiles MR; Kinchelow T; Patel IH
Clin Pharmacol Ther; 2002 Jul; 72(1):10-9. PubMed ID: 12152000
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.
Bellibas SE; Siddique Z; Dorr A; Bertasso A; Sista P; Kolis SJ; Cotler S; Delora P;
Pediatr Infect Dis J; 2004 Dec; 23(12):1137-41. PubMed ID: 15626952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
